Vital Farms stock rises as DA Davidson reiterates Buy rating

Vital Farms (VITL) stock has shown strong momentum, gaining 24.35% last week and trading near its 52-week high, following robust Q2 2025 results that significantly surpassed analyst consensus for revenue ($185M vs. $171M) and adjusted EPS ($0.36 vs. $0.28). Multiple firms, including DA Davidson, TD Cowen, Morgan Stanley, BMO Capital, and Telsey Advisory Group, have reiterated or raised price targets, citing the company's operational execution, successful price increases, capacity expansion, and its perceived 'scarcity value' amidst peer underperformance. This collective analyst confidence underscores a positive outlook for Vital Farms' sustained growth, with some projections indicating over 20% revenue growth through 2027.

Analysis

Vital Farms (VITL) is exhibiting significant operational and market momentum, underscored by its Q2 2025 results which substantially surpassed analyst expectations. The company reported revenue of $185 million against a consensus of $171 million, driven by a robust 15% year-over-year volume growth and successful price increases. This top-line strength was complemented by an adjusted EPS of $0.36, well ahead of the $0.28 consensus. In response, a broad cohort of investment firms, including DA Davidson, TD Cowen, Morgan Stanley, BMO Capital, and Telsey, have raised price targets to a range of $48-$51, reinforcing a bullish institutional outlook. The company's strategic execution is a key driver, highlighted by its ability to add partner farms and advance critical capacity expansions in Missouri and Indiana. This operational strength provides Vital Farms with a distinct "scarcity value" as competitors reportedly face weaker performance, positioning it favorably within the sector. Despite the stock's recent 24.35% gain and trading near its 52-week high, Morgan Stanley's projection of a 21% revenue growth rate from 2025 to 2027 suggests a sustained growth trajectory, although InvestingPro data indicates the current valuation is approaching fair value.

Key Decisions for Investors

• Given the unanimous analyst upgrades and price targets ranging from $48 to $51, maintaining a position seems warranted, but new investors should be cautious of the stock's recent 24% surge and proximity to its 52-week high.
• Closely monitor the execution of capital projects, specifically the capacity expansions in Missouri and Indiana, as their timely completion is crucial to sustaining the 20%+ revenue growth projected by analysts.
• Track the performance of sector peers, as Vital Farms' 'scarcity value' and valuation premium could be impacted by any significant changes in the competitive landscape.